Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/11/2022
• Auteurs : Romain TortuyauxFrédéric WalletPhilippe DerambureSaad Nseir
• Organismes : Centre Hospitalier Régional Universitaire [CHU Lille] Institut Pasteur de Lille Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576
• Publié dans Journal of Clinical Medicine le 29/10/2020

---

Résumé : Suspicion of bacterial aspiration pneumonia (BAP) is frequent during generalized convulsive status epilepticus (GCSE). Early identification of BAP is required in order to avoid useless antibiotic therapy. In this retrospective monocentric study, we aimed to determine the incidence of aspiration syndrome and BAP in GCSE requiring mechanical ventilation (MV) and factors associated with the occurrence of BAP. Patients were older than 18 years and had GCSE requiring MV. To distinguish BAP from pneumonitis, tracheal aspirate and quantitative microbiological criterion were used. Out of 226 consecutive patients, 103 patients (46%) had an aspiration syndrome, including 54 (52%) with a BAP. Staphylococcus aureus represented 33% of bacterial strains. No relevant baseline characteristics differed, including serum levels of CRP, PCT, and albumin. The median duration of treatment for BAP was 7 days (5–7). Patients with BAP did not have a longer duration of MV (p = 0.18) and ICU stay (p = 0.18) than those with pneumonitis. At 3 months, 24 patients (44%) with BAP and 10 (27%) with pneumonitis had a poor functional outcome (p = 0.06). In conclusion, among patients with GCSE, half of the patients had an aspiration syndrome and one-quarter suffered from BAP. Clinical characteristics and biomarkers were not useful for differentiating BAP from pneumonitis. These results highlight the need for a method to rapidly differentiate BAP from pneumonitis, such as polymerase-chain-reaction-based techniques.

---

Fichiers liés : P22.62 jcm-11-06673-v2.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/11/2022
• Auteurs : Adrien GrancherLudivine BeaussireSylvain ManfrediKarine Le MalicotMarie DutherageVincent VerdierClaire MulotOlivier BouchéJean-Marc PhélipCharles-Briac LevachéPhilippe DeguiralSophie CoutantDavid SefriouiJean-François EmilePierre Laurent-PuigFrédéric BibeauPierre MichelNasrin Sarafan-VasseurCôme LepageFrederic Di Fiore
• Organismes : Cancer and Brain Genomics CHU Rouen Cancer and Brain Genomics CHU Rouen Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Lipides - Nutrition - Cancer [Dijon - U1231] Lipides - Nutrition - Cancer [Dijon - U1231] Cancer and Brain Genomics CHU Rouen Cancer and Brain Genomics CHU Rouen Epigenetec Université de Reims Champagne-Ardenne Hôpital universitaire Robert Debré [Reims] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Clinique Francheville [Périgueux] Centre hospitalier de Saint-Nazaire Cancer and Brain Genomics CHU Rouen Cancer and Brain Genomics CHU Rouen AP-HP - Hôpital Ambroise Paré AP-HP - Hôpital Européen Georges Pompidou CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Cancer and Brain Genomics CHU Rouen Cancer and Brain Genomics CHU Rouen Lipides - Nutrition - Cancer [Dijon - U1231] Cancer and Brain Genomics CHU Rouen
• Publié dans Frontiers in Oncology le 26/10/2020

---

Résumé : Circulating tumor DNA (ctDNA) is reported to be promising in localized colorectal cancer (CRC). The present study aimed to retrospectively evaluate the impact of ctDNA in patients with a resected stage II CRC from the PROGIGE 13 trial with available paired tumor and blood samples. A group of recurrent patients were matched one-to-one with nonrecurrent patients according to sex, tumor location, treatment sequence, and blood collection timing. CtDNA was analyzed by digital PCR according to NGS of tumors. Disease-free survival (DFS) and overall survival (OS) were analyzed based on ctDNA, and the risks of recurrence and death were determined. A total of 134 patients were included, with 67 patients in each group. At least one alteration was identified in 115/134 tumors. Postoperative ctDNA was detected in 10/111 (9.0%) informative samples and was detected more frequently in the recurrent group (16.7% versus 1.8%; p = 0.02). The median DFS of ctDNA+ versus ctDNA- patients was 16.8 versus 54 months (p = 0.002), respectively, and the median OS was 51.3 versus 69.5 months (p = 0.03), respectively. CtDNA was associated with recurrence (ORa = 11.13, p = 0.03) and death (HRa = 3.15, p = 0.01). In conclusion, the presence of postoperative ctDNA is associated with both recurrence and survival in stage II CRC.

---

Fichiers liés : fonc-12-973167.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/11/2022
• Auteurs : Markus SchlaichMarc BelletBarthelemy von HallerParisa DanaietashGeorge BakrisJohn FlackRoland DreierMouna Sassi-SayadiLloyd HaskellKrzysztof NarkiewiczJi-Guang WangChristopher ReidMarkus SchlaichIvor KatzAndrew AjaniSinjini BiswasMurray EslerGrahame ElderSimon RogerDavid ColquhounJohn MooneyTine de BackerAlexandre PersuMartin ChaumontJean-Marie KrzesinskiThomas VanabscheGinette GirardLew PliammErnesto SchiffrinFatima MeraliGeorge DresserMichel ValleeShivinder JollyStephen ChowJiguang WangJianjun MuJing YuHong YuanYingqing FengXin ZhangJianhong XieLing LinMiroslav SoucekJiri WidimskyRenata CifkovaJan VaclavikMartin UllrychMartin LukacIvan RychlikThomas Guldager LauridsenIlkka KantolaJyrki TaurioOlavi UkkolaOlivier OrmezzanoPhilippe GosseMichel AziziPierre-Yves CourandPascal DelsartJean Michel TartiereFelix MahfoudRoland SchmiederJohannes StegbauerPhilipp LurzMichael KoziolekChristian OttNicole ToursarkissianKonstantinos TsioufisKonstantinos KyfnidisAthanasios ManolisSotirios PatsilinakosPantelis ZebekakisApostolos KaravidasPall DenesKatalin BezzeghMarianna ZsomLaszlo KovacsYehonatan SharabiMazen EliasIvetta SukholutskyChaim YosefyIrina KenisShaul AtarMassimo VolpeMuiesan Maria LorenzaStefano TaddeiGuido GrassiFranco VeglioJung Woo SonJang-Young KimJoong-Il ParkChang Hoon LeeHae-Young LeeRasa RaugalieneJolanta Elena MarcinkevicieneRoma KavaliauskieneJaap DeinumAbraham KroonBert-Jan van den BornAndrzej JanuszewiczAndrzej TykarskiJolanta WalczewskaZbigniew GaciongAndrzej WiecekMarzena ChrostowskaAndrzej KleinrokJan KrekoraGrzegorz KaniaAnna Podrazka-SzczepaniakCezary GolawskiMaciej PodziewskiBarbara KaczmarekGrzegorz SkoczylasAndrzej WilkolaskiIwona WozniakMarzena Janik-PalazzoloBarbara RewerskaAlexandra KonradiYuriy ShvartsTamara PecherinaKonstantin NikolaevGapon LiudmilaOlga OrlikovaViktor MordovinNatalia PetrochenkovaGadel KamalovElena KosmachevaKonstantin NikolaevVadim TyrenkoVladimir GorbunovAndrey ObrezanTatiana SupryadkinaIrina LerOleg KotenkoAnatoly KuzinFernando MartinezJosep RedonAnna OliverasLuis Beltran RomeroValerii ShatyloLeonid RudenkoAndriiy BazylevychYurii RudykOleksandr KarpenkoMykola StanislavchukVira TseluykoMykola KushnirErvin AsanovYuriy SirenkoAndriy YagenskyDavid CollierPankaj GuptaDavid WebbMary MacleodJames MclayAaron PeaceSamir AroraPatricia BuchananRobert HarrisRonald DegarmoMario GuillenAdam KarnsJoel NeutelYogesh PaliwalKarlton PettisPhillip TothJeffrey WayneBain ButcherPhillip DillerSuzanne OparilDavid CalhounDonald BrautigamJohn FlackJesse GoldmanArash RashidiNabeel AslamWilliam HaleyNabil AndrawisBrian LangRandy MillerJames PowellRobert DewhurstJames PritchardDinesh KhannaDennis TangNashwa GabraJean ParkConigliaro JonesCranford ScottBlanca LunaMurtaza MussajiRavi BhagwatMichael BauerJohn McgintyRajesh NambiarRenee SangrigoliWilliam Ross DavisWilliam EavesFrank McgrewAhmed AwadEric BolsterDavid ScottParamjit KaliraoPascal DabelWesley CalhounSteven GougeMark WarrenMary Katherine LawrenceAamir JamalMohamed El-ShahawyCarlos MercadoJayant KumarPedro Velasquez-MieyerRobert BuschTodd LewisLisa Rich
• Organismes : The University of Western Australia Baker Heart and Diabetes Institute State University of New York University of Chicago Biozentrum [Basel, Suisse] Medical University of Gdańsk Ruijin Hospital [Shanghai, Chine] University of Melbourne The University of Western Australia Baker Heart and Diabetes Institute Human Neurotransmitter Laboratory Imagerie Ultrasonore
• Publié dans The Lancet le 02/11/2020

---

Résumé : Background Resistant hypertension is associated with increased cardiovascular risk. The endothelin pathway has been implicated in the pathogenesis of hypertension, but it is currently not targeted therapeutically, thereby leaving this relevant pathophysiological pathway unopposed with currently available drugs. The aim of the study was to assess the blood pressure lowering efficacy of the dual endothelin antagonist aprocitentan in patients with resistant hypertension. Methods PRECISION was a multicentre, blinded, randomised, parallel-group, phase 3 study, which was done in hospitals or research centres in Europe, North America, Asia, and Australia. Patients were eligible for randomisation if their sitting systolic blood pressure was 140 mm Hg or higher despite taking standardised background therapy consisting of three antihypertensive drugs, including a diuretic. The study consisted of three sequential parts: part 1 was the 4-week double-blind, randomised, and placebo-controlled part, in which patients received aprocitentan 12•5 mg, aprocitentan 25 mg, or placebo in a 1:1:1 ratio; part 2 was a 32-week single (patient)-blind part, in which all patients received aprocitentan 25 mg; and part 3 was a 12-week double-blind, randomised, and placebo-controlled withdrawal part, in which patients were re-randomised to aprocitentan 25 mg or placebo in a 1:1 ratio. The primary and key secondary endpoints were changes in unattended office systolic blood pressure from baseline to week 4 and from withdrawal baseline to week 40, respectively. Secondary endpoints included 24-h ambulatory blood pressure changes. The study is registered on ClinicalTrials.gov, NCT03541174. Findings The PRECISION study was done from June 18, 2018, to April 25, 2022. 1965 individuals were screened and 730 were randomly assigned. Of these 730 patients, 704 (96%) completed part 1 of the study; of these, 613 (87%) completed part 2 and, of these, 577 (94%) completed part 3 of the study. The least square mean (SE) change in office systolic blood pressure at 4 weeks was-15•3 (SE 0•9) mm Hg for aprocitentan 12•5 mg,-15•2 (0•9) mm Hg for aprocitentan 25 mg, and-11•5 (0•9) mm Hg for placebo, for a difference versus placebo of-3•8 (1•3) mm Hg (97•5% CI-6•8 to-0•8, p=0•0042) and-3•7 (1•3) mm Hg (-6•7 to-0•8; p=0•0046), respectively. The respective difference for 24 h ambulatory systolic blood pressure was-4•2 mm Hg (95% CI-6•2 to-2•1) and-5•9 mm Hg (-7•9 to-3•8). After 4 weeks of withdrawal, office systolic blood pressure significantly increased with placebo versus aprocitentan (5•8 mm Hg, 95% CI 3•7 to 7•9, p<0•0001). The most frequent adverse event was mild-to-moderate oedema or fluid retention, occurring in 9%, 18%, and 2% for patients receiving aprocitentan 12•5 mg, 25 mg, and placebo, during the 4-week double-blind part, respectively. This event led to discontinuation in seven patients treated with aprocitentan. During the trial, a total of 11 treatment-emergent deaths occurred, none of which were regarded by the investigators to be related to study treatment. Interpretation In patients with resistant hypertension, aprocitentan was well tolerated and superior to placebo in lowering blood pressure at week 4 with a sustained effect at week 40.

---

Fichiers liés : 1-s2.0-S0140673622020347-main.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 06/11/2022
• Auteurs : Anne-Marie BaconNicolas BourgonElise DufourFabrice DemeterClément ZanolliKira E WestawayRenaud Joannes-BoyauPhilippe DuringerJean-Luc PoncheMike W MorleyEric SuzzoniSébastien FrangeulQuentin BoeschPierre-Olivier AntoineSouliphane BoualaphanePhonephanh SichanthongtipDaovee SihanamThi Mai NguyenAnh NguyenDenis FiorilloOlivier TombretElise Patole-EdoumbaTyler E DunnAlexandra ZachwiejaThonglith LuangkhothViengkeo SouksavatdyThongsa SayavongkhamdyLaura ShackelfordJean- Jacques Hublin
• Organismes : Biologie, anthropologie, biométrie, épigénétique, lignées : De la diversité des populations à l'individu, de l'identification à l'identité Ecole et Observatoire des Sciences de la Terre Laboratoire Image, Ville, Environnement Ecole et Observatoire des Sciences de la Terre

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/11/2022
• Auteurs : Nicholas FuggleNasser Al-DaghriOlivier BockJaime BrancoOlivier BruyèreEnrique CasadoEtienne CavalierBernard CortetMaarten de WitAndrea GiustiPhilippe HalboutNicholas HarveyMickaël HiligsmannJean-Marc KaufmanAndreas KurthStefania MaggiRadmila MatijevicSalvatore MinisolaSantiago PalaciosRégis Pierre RadermeckerFriederike ThomasiusSansin TuzunNicola VeroneseJohn KanisJean-Yves ReginsterRené RizzoliCyrus Cooper
• Organismes : Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490
• Publié dans Aging Clinical and Experimental Research le 27/10/2020

---

Résumé : Abstract Oral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still maintaining the efficacy of fracture risk reduction. Clinical trials and real-world data have been employed to demonstrate some benefits in terms of reduced upper gastro-intestinal adverse events, adherence, persistence and health economic outcomes. This report describes the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores where oral bisphosphonates sit in current clinical practice guidelines, review their risk–benefit profile and the consequences of poor adherence before exploring novel oral bisphosphonate formulations and their potential clinical and health economic impact. Further research is required but there are signs that these novel, oral bisphosphonate formulations may lead to improved tolerance of oral bisphosphonates and thus, improved adherence and fracture outcomes.

---

Source

---

• Type de publi. : Autre publication
• Date de publi. : 01/11/2022
• Auteurs : Philippe BouvetJean-Marc CavaillonJean-Claude DussauleSophie GayMarie-Pierre GosselinQuentin MerelAna NavarreteIngrid PfeiferNadia Senni
• Organismes : Agence Nationale de la Recherche Institut Pasteur [Paris] Agence Nationale de la Recherche Agence Nationale de la Recherche Agence Nationale de la Recherche Agence Nationale de la Recherche Agence Nationale de la Recherche Agence Nationale de la Recherche Agence Nationale de la Recherche Agence Nationale de la Recherche
• Publié dans Les Cahiers de l'ANR le 14/01/2010

---

Résumé : Le présent cahier dresse un historique et un état des lieux de la recherche sur l’antibiorésistance. Outre la présentation des appels à projets ayant contribué au financement de la recherche française dans ce domaine de 2011 à 2021, il propose une analyse des publications issues des projets financés ainsi qu’une sélection de projets de recherche.

---

Fichiers liés : ANR_cahier_14_antibioresistance.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2022
• Auteurs : Philippe ColsonJeremy DelerceElise Marion-ParisJean-Christophe LagierAnthony LevasseurPierre-Edouard FournierBernard La ScolaDidier Raoult
• Organismes : Microbes Evolution Phylogénie et Infections Vecteurs - Infections tropicales et méditerranéennes Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection Institut Hospitalier Universitaire Méditerranée Infection Microbes Evolution Phylogénie et Infections Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection Institut Hospitalier Universitaire Méditerranée Infection Vecteurs - Infections tropicales et méditerranéennes Microbes Evolution Phylogénie et Infections Vecteurs - Infections tropicales et méditerranéennes Microbes Evolution Phylogénie et Infections Institut Hospitalier Universitaire Méditerranée Infection
• Publié dans Infection, Genetics and Evolution le 27/10/2020

---

Fichiers liés : main (1).pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2022
• Auteurs : Mateo Sanchis-BorjaVincent FalletElisabeth FabreMarie WislezStéphane CulineGérard ZalcmanJean-Philippe SpanoNathalie Chabbert-BuffetFlorence CouletPatrick R BenusiglioJacques Cadranel
• Organismes : Service d'oncologie médicale [CHU HEGP] Service de pneumologie [CHU Cochin] Service d’oncologie thoracique et essais précoces [CHU Bichat] Epidémiologie, Systèmes d'Information, Modélisation
• Publié dans Lung Cancer le 27/10/2020

---

Résumé : Introduction: BRCA1 and BRCA2 (BReast CAncer susceptibility genes) are two tumor-suppressor genes associated with the hereditary breast and ovarian cancer susceptibility syndrome. Recent studies also suggest an increased lung adenocarcinoma risk in carriers. Methods: We conducted a multi-center retrospective study in 18 different French pulmonology and/or oncology departments on medico-administrative and clinical data prospectively collected in the Clinical Data Warehouse (CDW) of Greater Paris University Hospitals (Assistance Publique-Hôpitaux de Paris, AP-HP). Clinical characteristics and outcomes of patients with LC and a previously known BRCA1/2gl variant were retrospectively evaluated. Results: 17 patients with LC and known BRCA1/2gl variant were included. Patients were most women, former smokers with localized disease and BRCA2 variants. All LC were adenocarcinoma. For patients with medical history of cancer, median time from the first cancer in the BRCA spectrum and the LC occurrence was 20 years. Median disease-free survival (DFS) and overall survival (OS) in localized tumor (Stage I and II) was not reached and 78.6 months, respectively. In advanced cancer (Stade III and IV) median progression free survival was 9.7 months and median OS was 17.8 months. Univariate OS and DFS/PFS analyses by BRCA status did not find significant differences. Conclusion: Results seem to show particular LC features in carriers of BRCA2 variants: adenocarcinoma subtype, woman, former or non-smoker.

---

Fichiers liés : Characterization of lung cancers in patients with BRCA germline variants A multicenter series..pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2022
• Auteurs : Manon GirodStéphane DalleLaurent MortierSophie DalacMarie-Thèrèse LecciaCaroline DutriauxHenri MontaudiéJulie de QuatrebarbesThierry LesimpleFlorence Brunet-PossentiPhilippe SaiagEve MaubecDelphine LegoupilPierre-Emmanuel StoebnerJean Philippe ArnaultWendy LefevreCéleste LebbéOlivier Dereure
• Organismes : Centre Hospitalier Régional Universitaire [Montpellier] Centre de Recherche en Cancérologie de Lyon Hôpital Claude Huriez [Lille] Hôpital du Bocage Hôpital la Tronche Service de dermatologie [Bordeaux] Service de Dermatologie [Nice] Centre méditerranéen de médecine moléculaire Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois] CRLCC Eugène Marquis AP-HP - Hôpital Bichat - Claude Bernard [Paris] AP-HP - Hôpital Ambroise Paré Université de Versailles Saint-Quentin-en-Yvelines AP-HP - Hôpital Avicenne Centre Hospitalier Régional Universitaire de Brest Hôpital Universitaire Carémeau [Nîmes] Centre Hospitalier Universitaire d'Amiens-Picardie Service de Dermatologie [AP-HP Hôpital Saint-Louis] Service de Dermatologie [AP-HP Hôpital Saint-Louis] Centre Hospitalier Régional Universitaire [Montpellier] Pathogenesis and Control of Chronic and Emerging Infections
• Publié dans JCO precision oncology le 21/06/2020

---

Résumé : Purpose: Mitogen-activating protein kinase inhibitors (MAPKis) are largely used in V600E/K BRAF–mutated metastatic melanomas, but data regarding effectiveness of targeted therapy in patients with rare BRAF mutations and molecular description of these infrequent mutations are scarce. Patients and methods: A multicenter study was conducted on patients with metastatic melanoma harboring a well-identified mutation of BRAF and enrolled from March 2013 to June 2021 in the French nationwide prospective cohort MelBase. The molecular BRAF mutation pattern, response to MAPKis when applicable, and survival data were analyzed. Results: Of 856 selected patients, 51 (6%) harbored a non-V600E/K BRAF mutation involving codons V600 (24 of 51, 47%; V600G 27.4%, V600R 15.6%), K601 (6 of 51, 11.7%), and L597 (4 of 51, 7.8%). An objective response to MAPKis either BRAF inhibitor (BRAFi) alone or combined with MEK inhibitor was achieved in 56% (353 of 631) of V600E/K, 58% (11 of 19) of non-E/K V600, and 22% (2 of 9) of non-V600 BRAF-mutated patients, with a median progression-free survival of 7.7, 7.8, and 2.8 months, respectively. Overall, objective response rate was higher with BRAFi + MEK inhibitor combination than with BRAFi in monotherapy for each subset. Conclusion: Rare BRAF mutations are not anecdotal in the metastatic melanoma population. Although data interpretation must remain careful owing to the limited size of some subsets of patients, non-E/K V600 BRAF mutations seem to confer a high sensitivity to targeted therapy, whereas MAPKis seem less effective in patients with non-V600 BRAF mutations. However, this strategy may be used as an alternative option in the case of immunotherapy failure in the latter population.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2022
• Auteurs : Cyrille VessaireJean-Philippe ChancelierMichel de LaraPierre CarpentierAlejandro Rodríguez-MartínezAnna Robert
• Organismes : Centre d'Enseignement et de Recherche en Mathématiques et Calcul Scientifique Centre d'Enseignement et de Recherche en Mathématiques et Calcul Scientifique Centre d'Enseignement et de Recherche en Mathématiques et Calcul Scientifique Optimisation et commande TotalEnergies SE
• Publié dans Computers & Chemical Engineering le 30/10/2020

---

Résumé : In this paper, we propose a mathematical formulation for the management of an oil production network as a multistage optimization problem. The reservoir is modeled as a controlled dynamical system by using material balance equations. We use a dynamic programming algorithm to solve the optimization problem. Two numerical applications illustrate our work: the first one consists in optimizing the production of a gas reservoir, whereas the second one tackles an oil reservoir with water injection.

---

Fichiers liés : preprint_v2_Deterministic_Mbal_Reservoir.pdf

---

Source